Sodium Oxybate in Alcohol-Responsive Essential Tremor of Voice: An Open-Label Phase II Study

被引:3
|
作者
O'Flynn, Lena C. [1 ,2 ,3 ]
Frucht, Steven J. [4 ]
Simonyan, Kristina [1 ,2 ,3 ,5 ,6 ,7 ]
机构
[1] Massachusetts Eye & Ear, Dept Otolaryngol Head & Neck Surg, Boston, MA USA
[2] Harvard Med Sch, Boston, MA USA
[3] Harvard Univ, Program Speech Hearing Biosci & Technol, Boston, MA USA
[4] NYU Langone Hlth, Dept Neurol, New York, NY USA
[5] Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA
[6] Massachusetts Eye & Ear, Dept Otolaryngol Head & Neck Surg, 243 Charles St,Suite 421, Boston, MA 02114 USA
[7] Harvard Med Sch, 243 Charles St,Suite 421, Boston, MA 02114 USA
基金
美国国家卫生研究院;
关键词
voice tremor; sodium oxybate; treatment; alcohol; MOVEMENT-DISORDERS; SENSITIVITY; RECEPTORS; TARGETS; TRIAL;
D O I
10.1002/mds.29529
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BackgroundEssential tremor of voice (ETv) is characterized by involuntary oscillations of laryngeal and upper airway muscles, causing rhythmic alterations in pitch and loudness during both passive breathing and active laryngeal tasks, such as speaking and singing. Treatment of ETv is challenging and typically less effective compared with treatment of ET affecting extremities. ObjectiveWe conducted a proof-of-concept, open-label phase II study to examine the efficacy and central effects of sodium oxybate in patients with alcohol-responsive ETv. MethodsAll subjects received 1.0 to 1.5 g of oral sodium oxybate and underwent brain functional magnetic resonance imaging. The primary endpoint was the number of patients (% from total) with reduced ETv symptoms by at least 10% at about 40 to 45 minutes after sodium oxybate intake based on the combined visual analog scale score of ETv symptom severity. The secondary endpoint included changes in brain activity after sodium oxybate intake compared to baseline. ResultsSodium oxybate reduced ETv symptoms on average by 40.8% in 92.9% of patients. Drug effects were observed about 40 to 45 minutes after intake, lasting about 3.5 hours, and gradually wearing off by the end of the fifth hour. The central effects of sodium oxybate were associated with normalized activity in the cerebellum, inferior/superior parietal lobules, inferior frontal gyrus, and insula and re-established functional relationships between these regions. ConclusionsSodium oxybate showed high efficacy in ETv patients, with a likely central action on disorder pathophysiology. Sodium oxybate may be an effective novel oral drug for treatment of alcohol-responsive ETv patients. & COPY; 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
引用
收藏
页码:1936 / 1944
页数:9
相关论文
共 50 条
  • [31] A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy
    Black, J
    Guilleminault, C
    Bogan, R
    Feldman, N
    Hagaman, M
    Hertz, G
    Iyer, V
    Kathawalla, S
    Lankford, A
    Mitler, M
    Hayduk, R
    Sahota, P
    Roth, T
    Scharf, M
    Scrima, L
    Schwartz, J
    Zammit, G
    SLEEP, 2003, 26 (01) : 31 - 35
  • [32] Randomized, crossover, open-label study of the relative bioavailability and safety of FT218, a once-nightly sodium oxybate formulation: Phase 1 study in healthy volunteers
    Bogan, Richard
    Thorpy, Michael J.
    Winkelman, John W.
    Dubow, Jordan
    Gudeman, Jennifer
    Seiden, David
    SLEEP MEDICINE, 2022, 100 : 442 - 447
  • [33] The tolerability and efficacy of sodium oxybate (Xyrem®) as a treatment for ethanol-responsive, medication-refractory myoclonus and essential tremor (ET)
    Frucht, SJ
    Houghton, WC
    Bordelon, Y
    Louis, ED
    Greene, PE
    MOVEMENT DISORDERS, 2005, 20 (09) : 1240 - 1240
  • [34] A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis
    Tayek, John A.
    Stolz, Andrew A.
    Nguyen, Danh, V
    Fleischman, M. Wayne
    Donovan, John A.
    Alcorn, Joseph M.
    Chao, Daniel C-K
    Asghar, Aliya
    Morgan, Timothy R.
    ECLINICALMEDICINE, 2022, 54
  • [35] A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis
    Morgan, Timothy
    Asghar, Aliya
    Tayek, John
    Nguyen, Danh
    Fleischman, M. Wayne
    Donovan, John
    Alcorn, Joseph
    Chao, Daniel
    Stolz, Andrew
    JOURNAL OF HEPATOLOGY, 2022, 77 : S142 - S142
  • [36] An Open-Label, Phase 1b Study of the Neuroactive Steroid GABAA Receptor Positive Allosteric Modulator SAGE-324 in Essential Tremor
    Paskavitz, James
    Nguyen, David
    Qin, Min
    Wehr, Angela
    Doherty, James
    Kanes, Stephen
    NEUROLOGY, 2020, 94 (15)
  • [37] An Open-Label, Phase 1b Study of the Neuroactive Steroid GABAA Receptor Positive Allosteric Modulator SAGE-324 in Essential Tremor
    Colquhoun, H.
    Nguyen, D.
    Qin, M.
    Wehr, A.
    Doherty, J.
    Kanes, S.
    MOVEMENT DISORDERS, 2020, 35 : S32 - S32
  • [38] A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome
    Daver, N.
    Vega-Ruiz, A.
    Kantarjian, H. M.
    Estrov, Z.
    Ferrajoli, A.
    Kornblau, S.
    Verstovsek, S.
    Garcia-Manero, G.
    Cortes, J. E.
    EUROPEAN JOURNAL OF CANCER CARE, 2013, 22 (05) : 605 - 611
  • [39] An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma
    Kanai, Fumihiko
    Obi, Shuntaro
    Fujiyama, Shigetoshi
    Shiina, Shuichiro
    Tamai, Hideyuki
    Mochizuki, Hitoshi
    Koike, Yukihiro
    Imamura, Jun
    Yamaguchi, Takayoshi
    Saida, Isamu
    Yokosuka, Osamu
    Omata, Masao
    HEPATOLOGY INTERNATIONAL, 2014, 8 (01) : 94 - 103
  • [40] An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa
    Giamarellos-Bourboulis, E. J.
    Pelekanou, E.
    Antonopoulou, A.
    Petropoulou, H.
    Baziaka, F.
    Karagianni, V.
    Stavrianeas, N.
    Giamarellou, H.
    BRITISH JOURNAL OF DERMATOLOGY, 2008, 158 (03) : 567 - 572